Recent Progress of Irreversible BTK Inhibitors
DOI:
https://doi.org/10.62051/cwmdpx30Keywords:
Bruton tyrosine kinase inhibitor; ibrutinib; zanubrutinib; safety; specificity.Abstract
In recent years, Bruton tyrosine kinase (BTK) inhibitors that selectively inhibit B cell receptor (BCR) signaling have become a popular and effective treatment for lymphomas in the public. As the pivotal tyrosine kinase BTK regulates the BCR pathway, BTK inhibitors were developed to block the pathway by binding with BTK thereby relieving the B-cell lymphoma progression. Ibrutinib, the first-generation BTK inhibitor, can effectively inhibit BTK and alleviate various cancer diseases. However, ibrutinib's lack of selectivity has led to a series of side effects, having adverse effects on survival rates and tolerability. By altering the molecular structure, researchers have developed the next-generation irreversible BTK inhibitors aiming at increasing target specificity and decreasing off-target impacts, such as acalabrutinib, tirabrutinib, spebrutinib, branebrutinib, and zanubrutinib, who recently received approval by FDA. This article compares and analyzes the advantages and disadvantages of these irreversible BTK inhibitors, especially zanubrutinib, with ibrutinib and finally draws a conclusion.
Downloads
References
[1] R. Kuppers, Mechanisms of B-cell lymphoma pathogenesis, Nat. Rev. Cancer. 5 (2005) 251–262.
[2] C. Zhu, Z. Yang, Y. Zhang, et al, PROTAC for Bruton’s tyrosine kinase degradation alleviates inflammation in autoimmune diseases, Cell Discov. 10 (2024) 82 .
[3] A.B. Satterthwaite, O.N. Witte, The role of Bruton's tyrosine kinase inB-cell development and function: a genetic perspective, Immunol. Rev. 175 (2000) 120-127.
[4] J.A. Di Paolo, T. Huang, M. Balazs, et al, Specific Btk inhibition sup-presses B cell- and myeloid cell-mediated arthritis, Nat. Chem. Biol. 7 (2011) 41-50.
[5] S. Pal Singh, F. Dammeijer, R.W. Hendriks, Role of Bruton's tyrosine kinase in B cells and malignancies, Mol. Cancer. 17 (2018) 57.
[6] F.M. Uckun, H.E. Tibbles, A.O. Vassilev. Bruton's tyrosine kinase as a new therapeutic target, Anticancer Agents. Med. Chem. 7 (2007) 624-32.
[7] Y. Guo, Y. Liu, N. Hu, D. Yu, C. Zhou, G. Shi, B. Zhang, M. Wei, J. Liu, L. Luo, Z. Tang, H. Song, Y. Guo, X. Liu, D. Su, S. Zhang, X. Song, X. Zhou, Y. Hong, S. Chen, Z. Cheng, S. Young, Q. Wei, H. Wang, Q. Wang, L. Lv, F. Wang, H. Xu, H. Sun, H. Xing, N. Li, W. Zhang, Z. Wang, G. Liu, Z. Sun, D. Zhou, W. Li, L. Liu, L. Wang, Z. Wang, Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase, J. Med. Chem. 62 (2019) 7923-7940.
[8] L. Vargas, A. Hamasy, B.F. Nore, C.I. Smith, Inhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity, and inflammatory diseases, Scand. J. Immunol. 78 (2013) 130-139.
[9] J.A. Burger, Bruton's tyrosine kinase (BTK) inhibitors in clinical trials, Curr. Hematol. Malig. Rep. 9 (2014) 44-49.
[10] D. Rozkiewicz, J.M. Hermanowicz, I. Kwiatkowska, A. Krupa, D. Pawlak, Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials, Molecules. 28 (2023) 2400.
[11] L.M. Saleh, W. Wang, S.E. Herman, N.S. Saba, V. Anastas, E. Barber, M. Corrigan-Cummins, M. Farooqui, C. Sun, S.M. Sarasua, Z. Zhao, N.K. Abousamra, O. Elbaz, H.A. Abdelghaffar, A. Wiestner, K.R. Calvo, Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia, Leukemia. 31 (2017) 340-349.
[12] J. McCay, J.G. Gribben, The role of BTK inhibitors on the tumor microenvironment in CLL, Leuk Lymphoma. 63 (2022) 2023-2032.
[13] S.Varikuti, B. Singh, G. Volpedo, D.K. Ahirwar, B.K. Jha, N. Saljoughian, A.G. Viana, C. Verma, O. Hamza, G. Halsey, et al, Ibrutinib Treatment Inhibits Breast Cancer Progression and Metastasis by Inducing Conversion of Myeloid-Derived Suppressor Cells to Dendritic Cells, Br. J. Cancer. 122 (2020) 1005–1013.
[14] J.Wang, X. Liu, Y. Hong, S. Wang, P. Chen, A. Gu, X. Guo, P. Zhao, Ibrutinib, a Bruton’s Tyrosine Kinase Inhibitor, Exhibits Antitumoral Activity and Induces Autophagy in Glioblastoma, J. Exp. Clin. Cancer Res. 36 (2017) 96.
[15] E. Scheers, L. Leclercq, J. de Jong, N. Bode, M. Bockx, A. Laenen, F. Cuyckens, D. Skee, J. Murphy, J. Sukbuntherng, G. Mannens, Absorption, Metabolism, and Excretion of Oral 14C Radiolabeled Ibrutinib: An open-label, Phase 1, Single-dose Study in Healthy Men, Drug Metab. Dispos. 43 (2015) 289−297.
[16] C.S. Tam, S. Opat, S. D'Sa, W. Jurczak, H.P. Lee, G. Cull, R.G. Owen, P. Marlton, B.E. Wahlin, R.G. Sanz, H. McCarthy, S. Mulligan, A. Tedeschi, J.J. Castillo, J. Czyz, C. Fernández de Larrea, D. Belada, E. Libby, J.V. Matous, M. Motta, T. Siddiqi, M. Tani, M. Trneny, MC. Minnema, C. Buske, V. Leblond, J. Trotman, W.Y. Chan, J. Schneider, S. Ro, A. Cohen, J. Huang, M. Dimopoulos, A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study, Blood. 136 (2020) 2038-2050.
[17] J.C. Byrd, P. Hillmen, P. Ghia, A.P. Kater, A. Chanan-Khan, R.R. Furman, S. O'Brien, M.N. Yenerel, A. Illés, N. Kay, J.A. Garcia-Marco, A. Mato, J. Pinilla-Ibarz, J.F. Seymour, S. Lepretre, S. Stilgenbauer, T. Robak, W. Rothbaum, R. Izumi, A. Hamdy, P. Patel, K. Higgins, S. Sohoni, W. Jurczak, Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial, J. Clin. Oncol. 39 (2021) 3441-3452.
[18] J.C. Byrd, B. Harrington, S. O’Brien, J.A. Jones, A. Schuh, S. Devereux, J. Chaves, W.G. Wierda, F.T. Awan, J.R. Brown, et al, Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia, N. Engl. J. Med. 374 (2016) 323–332.
[19] A.H. Lipsky, N. Lamanna, Novel Combination Approaches with Targeted Agents in Frontline Chronic Lymphocytic Leukemia, Cancer 129 (2022) 18–31.
[20] T. Covey, T. Barf, M. Gulrajani, F. Krantz, B. van Lith, E. Bibikova, et al, Abstract 2596: ACP-196: a novel covalent Bruton’s tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients, Cancer Res. 75 (2015) 2596.
[21] X.J. Liu, X. Liu, X.J. Pang, X.Y. Yuan, G.X. Yu, Y.R. Li, Y.F. Guan, Y.B. Zhang, J. Song, Q.R. Zhang, SY. Zhang, Progress in the development of small molecular inhibitors of the Bruton's tyrosine kinase (BTK) as a promising cancer therapy, Bioorg. Med. Chem. 47 (2021) 116358.
[22] J. Wu, M. Zhang, D. Liu, Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor, J. Hematol. Oncol. 9 (2016) 21.
[23] A.P. Bye, A.J. Unsworth, M.J. Desborough, C.A.T. Hildyard, N. Appleby, D. Bruce, N. Kriek, S.H. Nock, T. Sage, C.E. Hughes, J.M. Gibbins, Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib, Blood Adv. 1 (2017) 2610–2623.
[24] V. Patel, K. Balakrishnan, E. Bibikova, M. Ayres, M.J. Keating, W.G. Wierda, V. Gandhi, Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells, Clin. Cancer Res. 23 (2017) 3734-3743.
[25] J.C. Byrd, B. Harrington, S. O'Brien, J.A. Jones, A. Schuh, S. Devereux, et al, Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia, N. Engl. J. Med. 374 (2016) 323–32.
[26] A. Vidal-Crespo, V. Rodríguez, A. Matas-Céspedes, E. Campos, A. López-Guillermo, G. Roué, et al, Abstract 1757: the novel BTK inhibitor CC-292 exerts in vitro and in vivo antitumor activity, interferes with adhesion, cell migration, and synergizes with lenalidomide in MCL models, Cancer Res. 74 (2014) 1757.
[27] S.E. Herman, X. Sun, E.M. McAuley, M.M. Hsieh, S. Pittaluga, M. Raffeld, D. Liu, K. Keyvanfar, C.M. Chapman, J. Chen, J.J. Buggy, G. Aue, J.F. Tisdale, P. Pérez-Galán, A. Wiestner, Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy, Leukemia. 27 (2013) 2311-21.
[28] S.E.M. Herman, A. Montraveta, C.U. Niemann, H. Mora-Jensen, M. Gulrajani, F. Krantz, R. Mantel, L.L. Smith, F. McClanahan, B.K. Harrington, D. Colomer, T. Covey, J.C. Byrd, R. Izumi, A. Kaptein, R. Ulrich, A.J. Johnson, B.J. Lannutti, A. Wiestner, J.A. Woyach, The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia, Clin. Cancer Res. 23 (2017) 2831-2841.
[29] H.L. Gardner*, B.K. Harrington*, R. Izumi, A. Hamdy, A. Kaptein, B.V. Lith, et al, Abstract 1744: ACP-196: a second generation Btk inhibitor demonstrates biologic activity in a canine model of B-cell non-Hodgkin lymphoma, Cancer Res. 74 (2014) 1744.
[30] S. Dhillon, Tirabrutinib: First Approval, Drugs. 80 (2020) 835-840.
[31] Y. Narita, M. Nagane, K. Mishima, Y. Terui, Y. Arakawa, H. Yonezawa, K. Asai, N. Fukuhara, K. Sugiyama, N. Shinojima, J. Kitagawa, A. Aoi, R. Nishikawa, Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma, Neuro. Oncol. 23 (2021) 122-133.
[32] T. Matsutani, S. Hirono, M. Kobayashi, Y. Higuchi, 10203-ML-6 TIRABRUTINIB FOR PRIMARY CNS LYMPHOMA: A SINGLE INSTITUTE RETROSPECTIVE ANALYSIS, Neuro-Oncology Advances. 5 (2023) v19–v20.
[33] N. Sekiguchi, S.Rai, W. Munakata, K. Suzuki, H. Handa, H. Shibayama, T. Endo, Y.Terui, N. Iwaki, N. Fukuhara, et al, Two-Year Outcomes of Tirabrutinib Monotherapy in Waldenström’s Macroglobulinemia, Cancer Sci. 113 (2022) 2085–2096.
[34] A.S. Abdelhameed, M.W. Attwa, N.S. Al-Shaklia, A.A. Kadi, A highly sensitive LC-MS/MS method to determine novel Bruton's tyrosine kinase inhibitor spebrutinib: application to metabolic stability evaluation, R. Soc. Open Sci. 6 (2019) 190434.
[35] J. Huang, Z. Ma, X. Peng, Z. Yang, Y. Wu, G. Zhong, T. Ouyang, Z. Chen, Y. Liu, Q. Wang, J. Chen, T. Chen, Z. Zeng, Discovery of Novel Potent and Fast BTK PROTACs for the Treatment of Osteoclasts-Related Inflammatory Diseases, J. Med. Chem. 67 (2024) 2438-2465.
[36] L.C. Arneson, K.J. Carroll, E.M. Ruderman, Bruton's Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis, Immunotargets Ther. 10 (2021) 333-342.
[37] E.K. Evans, R. Tester, S. Aslanian, R. Karp, M. Sheets, M.T. Labenski, S.R. Witowski, H. Lounsbury, P. Chaturvedi, H. Mazdiyasni, Z. Zhu, M. Nacht, M.I. Freed, R.C. Petter, A. Dubrovskiy, J. Singh, W.F. Westlin, Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans, J. Pharmacol. Exp. Ther. 346 (2013) 219-28.
[38] E.K. Evans, R. Tester, S. Aslanian, et al, Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans, J. Pharmacol. Exp. Ther. 346 (2013) 219–228.
[39] J.R. Brown, W.A. Harb, B.T. Hill, J. Gabrilove, J.P. Sharman, M.T. Schreeder, P.M. Barr, J.M. Foran, T.P. Miller, J.A. Burger, K.R. Kelly, D. Mahadevan, S. Ma, Y. Li, D.W. Pierce, E. Barnett, J. Marine, M. Miranda, A. Azaryan, X. Yu, P. Nava-Parada, J. Mei, T.J. Kipps, Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia, Haematologica. 101 (2016) e295-8.
[40] P.H. Schafer, A.J. Kivitz, J. Ma, S. Korish, D. Sutherland, L. Li, A. Azaryan, J. Kosek, M. Adams, L. Capone, et al, Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study, Rheumatol. 7 (2020) 101–119.
[41] S.H. Watterson, Q. Liu, M. Beaudoin Bertrand, et al, Discovery of branebrutinib (BMS-986195): a strategy for identifying a highly potentand selective covalent inhibitor providing rapid in vivo inactivation ofBruton's tyrosine kinase (BTK), J. Med. Chem. 62 (2019) 3228-3250.
[42] I.M. Catlett, M. Nowak, S. Kundu, N. Zheng, A. Liu, B. He, I.G. Girgis, D.M. Grasela, Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS-986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo-controlled trial in healthy participants, Br. J. Clin. Pharmacol. 86 (2020) 1849-1859.
[43] Information on: https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3936761/.
[44] Y.Y. Syed, Zanubrutinib: First Approval, Drugs. 80 (2020) 91-97.
[45] C.S.L. Tam, S. Opat, P. Marlton, et al, Three-year follow-up of treatment-naive and previously treated patients with Waldenström macroglobulinemia (WM) receiving single-agent zanubrutinib, J. Clin. Oncol. 38 (2020) 8051.
[46] C.S. Tam, J.L. Muñoz, J.F. Seymour, S. Opat, Zanubrutinib: past, present, and future, Blood Cancer J. 13 (2023) 141.
[47] C.S. Tam, J. Trotman, S. Opat, J.A. Burger, G. Cull, D. Gottlieb, R. Harrup, P.B. Johnston, P. Marlton, J. Munoz, J.F. Seymour, D. Simpson, A. Tedeschi, R. Elstrom, Y. Yu, Z. Tang, L. Han, J. Huang, W. Novotny, L. Wang, A.W. Roberts, Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL, Blood. 134 (2019) 851-859.
[48] C. Tam, A.P. Grigg, S. Opat, M. Ku, M. Gilbertson, M.A. Anderson, et al, The BTK inhibitor, Bgb-3111, is safe, tolerable, and highly active in patients with relapsed/refractory B-cell malignancies: initial report of a phase 1 first-in-human trial, Blood. 126 (2015) 832.
[49] Y. Song, M. Sun, J. Qi, W. Xu, J. Zhou, D. Li, J. Li, L. Qiu, C. Du, H. Guo, J. Huang, Z. Tang,Y. Ou, B. Wu, Y. Yu, J. Zhu, A two-part, single-arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B-cell malignancies, Br. J. Haematol. 198 (2022) 62-72.
[50] J.J. Shatzel, S.R. Olson, D.L. Tao, O.J.T. McCarty, A.V. Danilov, TG. DeLoughery, Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies, J. Thromb. Haemost. 15 (2017) 835-847.
[51] P. Hillmen, B. Eichhorst, J.R. Brown, N. Lamanna, S.M. O'Brien, C.S. Tam, L. Qiu, M. Kazmierczak, K. Zhou, M. Šimkovič, J. Mayer, A. Gillespie-Twardy, M. Shadman, A. Ferrajoli, P.S. Ganly, R. Weinkove, S. Grosicki, A. Mital, T. Robak, A. Österborg, H.A. Yimer, T. Salmi, M. Ji, J. Yecies, A. Idoine, K. Wu, J. Huang, W. Jurczak, Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial, J. Clin. Oncol. 41 (2023) 1035-1045.
[52] J. Muñoz, J. Paludo, S. Sarosiek, J.J. Castillo, Coming of Age for BTK Inhibitor Therapy: A Review of Zanubrutinib in Waldenström Macroglobulinemia, Cells. 11 (2022) 3287.
[53] N. Alrawashdh, A. McBride, M. Slack, D. Persky, L. Andritsos, I. Abraham, Cost-effectiveness and value of information analyses of Bruton's tyrosine kinase inhibitors in the treatment of relapsed or refractory mantle cell lymphoma in the United States, J. Manag. Care. Spec. Pharm. 28 (2022) 390-400.
Downloads
Published
Conference Proceedings Volume
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
